Croda International PLC

Croda International creates, makes, and sells specialty chemicals. Co.'s sales, marketing and research activities are organized into four global market sectors: Personal Care, which focuses on ingredients for skin, hair, sun protection and color cosmetic products; Life Sciences, which comprises of three complementary businesses: Health Care, Crop Protection, and Seed Enhancement; Performance Technologies, which targets technologies in Smart Materials and Energy Technologies and continues to develop its presence in Home Care and Water Treatment; and Industrial Chemicals, which is a sector based on selling co-streams, developing niche industrial applications and undertaking toll processing.
  • TickerCRDA
  • ISINGB00BYZWX769
  • ExchangeLondon Stock Exchange
  • SectorChemicals
  • CountryUnited Kingdom

Analysts

GlobalData Department

Croda International Plc (CRDA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary Croda International Plc (Croda) is a chemical company, which produces and sells specialty chemicals. The company’s product portfolio includes traditional and microwave plant extracts, active ingredients and cosmetic oils among others used in coatings & polymers, crop care, geo technologies, health care, home care, industrial chemicals, lubricants, personal care and polymer additives. It offers products to various sectors including consumer care, Personal care, Life sciences and Performance technologies, Industrial chemicals. Geographically, the company’s operations are spread across ...

Valérie GASTALDY

Analyse court terme - CRODA INTERNATIONAL PLC : La tendance est incertaine.

La tendance est incertaine. Les cours baissent, mais la tendance manque de puissance pour le moment. Le prochain support est à 4 332,38 p.

Valérie GASTALDY

Short term view - CRODA INTERNATIONAL PLC : The trend is uncertain.

The trend is uncertain. Prices are falling, but the trend is lacking power for the time being. The next support is at 4,332.38 p.

Rob Hales

Morningstar | Solid Growth Continues for Croda in 3Q; Shares Overvalued

We are maintaining our GBX 4,000 fair value estimate for narrow-moat Croda after reviewing the third-quarter trading update. At current levels, the shares look overvalued. Constant currency sales growth was 3.4% for the group and 4.5% in the core business, led by the life sciences segment. This is tracking in line with our expectations for the year. Sales for new, patented, or protected products, or NPP, reached 28.4%. Margins were reported to be slightly ahead of 2017 on a year-to-date basis. Personal care continued to be strong with 4.9% constant currency sales growth in the third quarter o...

Rob Hales

Solid Growth Continues for Croda in 3Q; Shares Overvalued

We are maintaining our GBX 4,000 fair value estimate for narrow-moat Croda after reviewing the third-quarter trading update. At current levels, the shares look overvalued. Constant currency sales growth was 3.4% for the group and 4.5% in the core business, led by the life sciences segment. This is tracking in line with our expectations for the year. Sales for new, patented, or protected products, or NPP, reached 28.4%. Margins were reported to be slightly ahead of 2017 on a year-to-date basis. ...

Rob Hales

Morningstar | Solid Growth Continues for Croda in 3Q; Shares Overvalued

We are maintaining our GBX 4,000 fair value estimate for narrow-moat Croda after reviewing the third-quarter trading update. At current levels, the shares look overvalued. Constant currency sales growth was 3.4% for the group and 4.5% in the core business, led by the life sciences segment. This is tracking in line with our expectations for the year. Sales for new, patented, or protected products, or NPP, reached 28.4%. Margins were reported to be slightly ahead of 2017 on a year-to-date basis. Personal care continued to be strong with 4.9% constant currency sales growth in the third quarter o...

Rob Hales

Solid Growth Continues for Croda in 3Q; Shares Overvalued

We are maintaining our GBX 4,000 fair value estimate for narrow-moat Croda after reviewing the third-quarter trading update. At current levels, the shares look overvalued. Constant currency sales growth was 3.4% for the group and 4.5% in the core business, led by the life sciences segment. This is tracking in line with our expectations for the year. Sales for new, patented, or protected products, or NPP, reached 28.4%. Margins were reported to be slightly ahead of 2017 on a year-to-date basis. ...

Rob Hales

Morningstar | Croda's first half reveals impressive margin improvement in performance technologies.

Croda is a British speciality chemicals company, known as the leader in skincare active ingredients for the personal-care market. Actives are a niche segment, but they have the highest value, as they allow companies to make performance marketing claims for their products, such as antiwrinkle creams. Continuous innovation and entrenched customer relationships have driven EBIT margins in Croda’s personal-care segment to nearly 35% in recent times, and contribution to group EBIT is now a hefty 47%. A key driver for the company is the percentage of sales from new, patented, or protected products. ...

Rob Hales

Croda's first half reveals impressive margin improvement in performance technologies.

Narrow-moat Croda reported first-half results that were broadly in line with our expectations. Adjusted operating profit was GBP 179 million, up 6% in constant currencies over the prior-year period. We are impressed with the margin improvement in the performance technologies segment. In the first half, operating margin in the segment reached 19.3% due to demarketing low-value products, primarily for the oil and gas market. As a result, performance technologies adjusted operating profit in consta...

Rob Hales

Morningstar | Croda’s 1H Reveals Impressive Margin Improvement in Performance Technologies; Shares Overvalued

Narrow-moat Croda reported first-half results that were broadly in line with our expectations. Adjusted operating profit was GBP 179 million, up 6% in constant currencies over the prior-year period. We are impressed with the margin improvement in the performance technologies segment. In the first half, operating margin in the segment reached 19.3% due to demarketing low-value products, primarily for the oil and gas market. As a result, performance technologies adjusted operating profit in constant currencies was up 15.2% over 2017, despite volumes shrinking 9%. We previously expected performan...

Eight Directors sold after exercising options/sold 24,659 shares at 3,934p.

Eight Directors at Croda International sold after exercising options/sold 24,659 shares at 3,934p. The significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted und...

CRODA INTERNATIONAL PLC. sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of CRODA INTERNATIONAL PLC. (GB), active in the Specialty Chemicals industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date October 19, 2018, the closing price was GBp 4,722.00 and its target price was estimated at GBp 4,485.90.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

GlobalData Department

Croda International Plc (CRDA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary Croda International Plc (Croda) is a chemical company, which produces and sells specialty chemicals. The company’s product portfolio includes traditional and microwave plant extracts, active ingredients and cosmetic oils among others used in coatings & polymers, crop care, geo technologies, health care, home care, industrial chemicals, lubricants, personal care and polymer additives. It offers products to various sectors including consumer care, Personal care, Life sciences and Performance technologies, Industrial chemicals. Geographically, the company’s operations are spread across ...

Expert Corporate Governance Service (ECGS)

Etude de l'AG du 26/04/2017

Item 3: Approve the remuneration report. The structure is generally acceptable, though there is concern with the possibility for accelerated vesting of the LTIP. Variable remuneration has the potential to be excessive, but was not during the year. However, the annual bonus only uses one performance metric and targets are not disclosed so it is unclear whether the bonus adequately aligns pay with performance.Item 13: Re-appoint the auditors. PricewaterhouseCoopers LLP (PwC) has been the external auditors of the Group since 1970. The tenure of the auditors is extremely long, which clearly may un...

Valérie GASTALDY

Analyse court terme - CRODA INTERNATIONAL PLC : La tendance est incertaine.

La tendance est incertaine. Les cours baissent, mais la tendance manque de puissance pour le moment. Le prochain support est à 4 332,38 p.

Valérie GASTALDY

Short term view - CRODA INTERNATIONAL PLC : The trend is uncertain.

The trend is uncertain. Prices are falling, but the trend is lacking power for the time being. The next support is at 4,332.38 p.

Valérie GASTALDY

Short term view - CRODA INTERNATIONAL PLC : The trend is bearish.

The trend is bearish. Prices are falling again, but the movement has become hesitant. The next support is at 4,332.38 p. The bearish trend would be challenged above 5,330.00 p.

Valérie GASTALDY

Analyse court terme - CRODA INTERNATIONAL PLC : La tendance est baissière.

La tendance est baissière. Les prix baissent à nouveau, mais le mouvement est devenu hésitant. Le prochain support est à 4 332,38 p. La tendance baissière serait remise en cause au-dessus de 5 330,00 p.

Valérie GASTALDY

Analyse moyen terme - CRODA INTERNATIONAL PLC : La tendance de fond est clairement orientée à la hausse.

La tendance de fond est clairement orientée à la hausse. La correction en cours gagne en vigueur. Il est trop tôt pour parler de retournement baissier. La tendance serait invalidée sous le support à 4 661,27 p.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch